Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion

J Thorac Oncol. 2019 Feb;14(2):e29-e30. doi: 10.1016/j.jtho.2018.10.169.

Authors

Terrence C Tsou¹, Kyle Gowen², Siraj M Ali², Vincent A Miller², Alexa B Schrock², Christine M Lovly³, Karen L Reckamp⁴

Affiliations

¹ City of Hope Comprehensive Cancer Center, Duarte, California.
² Foundation Medicine, Inc., Cambridge, Massachusetts.
³ Vanderbilt University Medical Center, Nashville, Tennessee.
⁴ City of Hope Comprehensive Cancer Center, Duarte, California. Electronic address: [email protected].

PMID: 30683295
DOI: 10.1016/j.jtho.2018.10.169

No abstract available

Publication types

Letter
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung*
Humans
Lung Neoplasms*
Nerve Tissue Proteins
Protein Kinase Inhibitors
Receptor Protein-Tyrosine Kinases
Transcription Factors

Substances

MYT1L protein, human
Nerve Tissue Proteins
Protein Kinase Inhibitors
Transcription Factors
Receptor Protein-Tyrosine Kinases